Paul Stoffels, Johnson & Johnson

Paul Stoffels, Johnson & Johnson ($JNJ)
2012 Pay Package: $7.34 million
2011 Pay Package: N/A (Stoffels became chief scientific officer in October 2012)
2012 Compensation: $825,385 in salary; $1.93 million in stock awards; $1.02 million in option awards; $2.3 million in incentive pay; $1.10 million in pension growth and deferred compensation; $161,466 in other compensation

Johnson & Johnson's Janssen has achieved major successes recently, including the tuberculosis drug Sirturo, which gained FDA approval at the end of 2012. It is the first drug to treat multi-drug resistant tuberculosis, a growing problem, and the first novel therapy approved for TB in 40 years. The pharma company has suffered some setbacks, too. The Alzheimer's drug bapineuzumab, which J&J and Pfizer were developing together, failed spectacularly in a late-stage trial, prompting J&J to slash 130 jobs and rethink its strategy for the disease. But with the FDA's approval of the diabetes-fighting SGLT2 inhibitor Invokana (canagliflozin) in March 2013, the company may have another blockbuster on its hands. And the company continues to ink major R&D deals, including the recent $1 billion buyout of Aragon Pharmaceuticals and its promising new therapy for prostate cancer. 

Many analysts, though, have begun to get restive, looking for more advances to propel future gains.

A physician by training, Paul Stoffels became the head of development for infectious diseases at Janssen Research Foundation in Beerse, Belgium, in 1991 and became CEO of Tibotec-Virco, a biopharma focused on viral diseases, in 1997. Johnson & Johnson bought that company in 2002, and Stoffels took responsibility for the unit. Since 2009, he has served as global head of Johnson & Johnson Pharmaceutical Research & Development.

For more:
Special Report: Paul Stoffels - The 25 most influential people in biopharma today - 2013
In revamped early-stage drive, J&J's Stoffels lets his biotech flag fly
J&J's pharma chairman lands 'more deals' in Boston innovation push
J&J wins first FDA approval for new class of diabetes drug

-- Emily Mullin

Paul Stoffels, Johnson & Johnson

Suggested Articles

With a new research team, outlook and more than a little help from the tech world, GSK has been quietly going about shoring up its pipeline.

The World Health Organization has called out Big Pharma for its dearth of antibiotic innovation amid a growing threat of antimicrobial resistance.

The trial hit its primary endpoint by the time of an interim analysis, enabling Chi-Med to stop the study and start work on a filing for approval.